Drug Profile
CP 463755
Latest Information Update: 17 Mar 2003
Price :
$50
*
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Dinoprostone agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Fracture
Most Recent Events
- 17 Mar 2003 No development reported - Preclinical for Fracture treatment in USA (unspecified route)
- 05 Mar 2001 Preclinical development for Fracture treatment in USA (Unknown route)